These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 15661094)

  • 21. 10 years of interferon beta-1b (Beta feron therapy.
    Kappos L; Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii1-iii2. PubMed ID: 16170493
    [No Abstract]   [Full Text] [Related]  

  • 22. [Drug therapy of multiple sclerosis].
    Kinnunen E
    Duodecim; 1999; 115(4):403-7. PubMed ID: 11830889
    [No Abstract]   [Full Text] [Related]  

  • 23. Interferon beta in the treatment of multiple sclerosis--closing remarks.
    Kappos L
    Mult Scler; 1995; 1 Suppl 1():S64-6. PubMed ID: 9345403
    [No Abstract]   [Full Text] [Related]  

  • 24. Approaches to neuroprotective strategies in multiple sclerosis.
    Tselis A; Khan OA; Lisak RP
    Expert Opin Pharmacother; 2010 Dec; 11(17):2869-78. PubMed ID: 20687779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The BCTRIMS expanded consensus on treatment of multiple sclerosis: II. The evidences for the use of glucocorticoids and immunomodulatory treatments].
    Moreira MA; Lana-Peixoto MA; Callegaro D; Haussen SR; Gama PD; Gabbai AA; Rocha FC; Lino AM;
    Arq Neuropsiquiatr; 2002 Sep; 60(3-B):875-80. PubMed ID: 12364966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-beta1a treatment for multiple sclerosis.
    Sandberg-Wollheim M
    Expert Rev Neurother; 2005 Jan; 5(1):25-34. PubMed ID: 15853471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
    Gusev EI; Boĭko AN; Pozer Ch
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
    [No Abstract]   [Full Text] [Related]  

  • 28. Multiple sclerosis to date: diagnosis, epidemiology, new aspects of the pathomechanism and the therapy.
    Bencsik K
    Ideggyogy Sz; 2004 Jan; 57(1-2):41-50. PubMed ID: 15042868
    [No Abstract]   [Full Text] [Related]  

  • 29. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-beta1b for multiple sclerosis.
    Burks J
    Expert Rev Neurother; 2005 Mar; 5(2):153-64. PubMed ID: 15853486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and disease modifying treatments in multiple sclerosis.
    Zajicek J
    Postgrad Med J; 2005 Sep; 81(959):556-61. PubMed ID: 16143683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mechanisms of development of neurodegenerative processes in multiple sclerosis: neuroprotective influence of beta-interferons today and neurotrophic factors -- tomorrow].
    Boĭko AN; Petrov SV; Nesterova VA; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):83-90. PubMed ID: 12938641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
    Neuhaus O; Stüve O; Archelos JJ; Hartung HP
    J Neurol Sci; 2005 Jun; 233(1-2):173-7. PubMed ID: 15949504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to interferon-beta treatment and results of therapy switching.
    Clerico M; Barbero P; Contessa G; Ferrero C; Durelli L
    J Neurol Sci; 2007 Aug; 259(1-2):104-8. PubMed ID: 17376486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current treatment of multiple sclerosis with interferon beta].
    Martín R
    Rev Neurol; 1998 Jul; 27(155):133-59. PubMed ID: 9674046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Certain problems of therapy with beta-interferon preparations].
    Gusev EI; Demina TL; Boĭko AN; Khachanova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):98-102. PubMed ID: 12938643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Magnetic resonance angiography in multiple sclerosis].
    Pati DV; Vorobeĭchik G
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):53-7. PubMed ID: 10629934
    [No Abstract]   [Full Text] [Related]  

  • 38. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interferons and neurologic diseases].
    Vermersch P; de Seze J; Ferriby D; Stojkovic T
    Rev Med Interne; 2002 Nov; 23 Suppl 4():475s-480s. PubMed ID: 12481402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments.
    Achiron A; Barak Y; Gail M; Mandel M; Pee D; Ayyagari R; Rotstein Z
    Breast Cancer Res Treat; 2005 Feb; 89(3):265-70. PubMed ID: 15754125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.